Clinical Trial Update: A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

Phase 4 study of tocilizumab as monotherapy or in combination with DMARDs in moderate-to-severe rheumatoid arthritis; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab) (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2014-07-22